Loading
NASDAQHealthcareBiotechnology
Latest quote
$8.195
+$0.185 · +2.31%
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Regular session
$8.195
+$0.185 · +2.31%
Regular session · ET · Market data may be delayed.
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Day range
Current $8.195
52-week range
Current $8.195
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
32
Expensive
Sentiment
44
Mixed
Risk
56
Elevated Risk
Momentum
54
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Day range
Current $8.195
52-week range
Current $8.195
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 24.61M USD | 19.06M USD | 13.11M USD | 7.84M USD | 8.77M USD |
| Selling, general, and administrative | 9.78M USD | 7.62M USD | 8.16M USD | 6.16M USD | 4.88M USD |
| Operating expenses | 34.4M USD | 26.68M USD | 21.27M USD | 14M USD | 13.65M USD |
| Interest income | — | 2.3M USD | — | — | — |
| Depreciation and amortization | 43K USD | 39K USD | 30K USD | 25K USD | 24K USD |
| Operating income | −34.4M USD | −26.68M USD | −21.27M USD | −14M USD | −13.65M USD |
| Net income | −32.77M USD | −24.44M USD | −19.38M USD | −13.68M USD | −13.59M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$8.33
1.65% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 15, 2018 | 1:20 | — | — |
Effective Nov 15, 2018
1:20
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM7.64M0.01%77.7B USD0.19%$278.3+0.26%
iShares Russell 2000 Growth ETFIWO2.75M0.02%14.04B USD0.24%$355.51+0.58%
Vanguard Extended Market ETFVXF2.29M0.00%95.4B USD0.05%$234.26+0.48%
Vanguard Russell 2000 ETFVTWO1.33M0.01%18B USD0.06%$112.41+0.28%
iShares Micro-Cap ETFIWC919.37K0.07%1.32B USD0.60%$182.68-0.06%
Vanguard Russell 2000 Growth ETFVTWG257.27K0.01%1.7B USD0.06%$259.55+0.55%
iShares Russell 2500 ETFSMMD160.77K0.00%4B USD0.23%$86.12+0.19%
Global X - Russell 2000 ETFRSSL141.04K0.01%1.41B USD0.08%$108.88+0.01%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDGlobal X - Russell 2000 ETFRSSLAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
